Th17 cell master transcription factor RORC2 regulates HIV-1 gene expression and viral outgrowth

Among CD4(+) T cells, T helper 17 (Th17) cells are particularly susceptible to HIV-1 infection and are depleted from mucosal sites, which causes damage to the gut barrier, resulting in a microbial translocation-induced systemic inflammation, a hallmark of disease progression. Furthermore, a proportion of latently infected Th17 cells persist long term in the gastrointestinal lymphatic tract where a low-level HIV-1 transcription is observed. This residual viremia contributes to chronic immune activation. Thus, Th17 cells are key players in HIV pathogenesis and viral persistence. It is, however, unclear why these cells are highly susceptible to HIV-1 infection. Th17 cell differentiation depends on the expression of the master transcriptional regulator RORC2, a retinoic acid-related nuclear hormone receptor that regulates specific transcriptional programs by binding to promoter/enhancer DNA. Here, we report that RORC2 is a key host cofactor for HIV replication in Th17 cells. We found that specific inhibitors that bind to the RORC2 ligand-binding domain reduced HIV replication in CD4(+) T cells. The depletion of RORC2 inhibited HIV-1 infection, whereas its overexpression enhanced it. RORC2 was also found to promote HIV-1 gene expression by binding to the nuclear receptor responsive element in the HIV-1 long terminal repeats (LTR). In treated HIV-1 patients, RORC2(+) CD4 T cells contained more proviral DNA than RORC22(-) cells. Pharmacological inhibition of RORC2 potently reduced HIV-1 outgrowth in CD4(+) T cells from antiretroviral-treated patients. Altogether, these results provide an explanation as to why Th17 cells are highly susceptible to HIV-1 infection and suggest that RORC2 may be a cell-specific target for HIV-1 therapy.

Automated summary

Th17 cells are highly susceptible to HIV-1 infection and play a crucial role in viral persistence and disease progression. The master transcriptional regulator RORC2 is essential for Th17 cell differentiation and functions as a key host cofactor for HIV replication. Pharmacological inhibition of RORC2 may be a potential cell-specific target for HIV-1 therapy.